SH2D1B Interacts with GLUT1, Potential Drug Target Or Biomarker for Insulin Resistance

Target Name: SH2D1B

NCBI ID: G117157

SH2D1B

SH2D1B Interacts with GLUT1, Potential Drug Target Or Biomarker for Insulin Resistance

SH2D1B (SH21B_HUMAN) is a protein that is expressed in various tissues of the human body, including the liver, pancreas, and blood cells. Its primary function is to help regulate the levels of glucose in the body by carrying out a critical role in insulin signaling.

insulin is a hormone that is produced by the pancreas and helps to regulate the levels of glucose in the blood. When the body's blood sugar levels become too high, the insulin hormone causes the liver to release glucose into the bloodstream to lower them. Conversely, when the body's blood sugar levels become too low, insulin causes the liver to stop producing glucose and instead store glucose in the muscle and fat cells.

The SH2D1B protein plays a crucial role in regulating the levels of glucose in the body by helping to regulate the amount of insulin that is released by the pancreas. It does this by interacting with a protein called GLUT1, which is also known as the GLUT1 receptor.

GLUT1 is a transmembrane protein that is expressed in various tissues of the body, including the pancreas, liver, and blood cells. It is involved in glucose metabolism by helping to regulate the levels of glucose in the blood.

SH2D1B has been shown to interact with GLUT1 and can cause changes in the way that GLUT1 functions. This interaction between SH2D1B and GLUT1 could be a potential drug target or biomarker for the treatment of various diseases associated with insulin resistance, such as type 2 diabetes.

In addition to its role in regulating insulin sensitivity, SH2D1B is also involved in the regulation of cellular signaling pathways that are important for maintaining cellular health and function.

SH2D1B is a protein that is expressed in various tissues of the human body, including the liver, pancreas, and blood cells. Its primary function is to help regulate the levels of glucose in the body by carrying out a critical role in insulin signaling. The SH2D1B protein plays a crucial role in regulating the levels of glucose in the body by helping to regulate the amount of insulin that is released by the pancreas. It does this by interacting with a protein called GLUT1, which is also known as the GLUT1 receptor. This interaction between SH2D1B and GLUT1 could be a potential drug target or biomarker for the treatment of various diseases associated with insulin resistance.

Protein Name: SH2 Domain Containing 1B

Functions: Cytoplasmic adapter regulating receptors of the signaling lymphocytic activation molecule (SLAM) family such as CD84, SLAMF1, LY9 and CD244 (PubMed:11689425). In SLAM signaling seems to cooperate with SH2D1A/SAP. Plays a role in regulation of effector functions of natural killer (NK) cells by controlling signal transduction through CD244/2B4 without effecting its tyrosine phosphorylation; downstream signaling involves PLCG1 and ERK activation (PubMed:24687958). Activation of SLAMF7-mediated NK cell function does not effect receptor tyrosine phosphorylation but distal signaling (By similarity). In the context of NK cell-mediated cytotoxicity does not enhance conjugate formation with target cells but stimulates polarization of the microtubule-organizing center and cytotoxic granules toward the NK cell synapse (PubMed:24687958). Negatively regulates CD40-induced cytokine production in dendritic cells downstream of SLAM family receptors probably by inducing activation of the PI3K pathway to inhibit p38 MAPK and JNK activation (By similarity)

The "SH2D1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH2D1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets